Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis wraps up Eon

Executive Summary

Sandoz, Hexall AG and newly added Eon Labs are expected to generate more than 80 generic approvals per year, the parent company says July 21. Novartis completed the acquisition of Eon two days after receiving clearance from the Federal Trade Commission. Under a proposed consent order with FTC, Novartis agreed to divest three generic drugs - Sandoz' muscle relaxant orphenadrine and tuberculosis treatment rifampin, and Eon's antidepressant desipramine - to Amide Pharmaceuticals. "The Pink Sheet" (1July 18, In Brief) incorrectly identified desipramine as a Sandoz drug and rifampin as an Eon product...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS046124

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel